The Structure of Phosphorylated GSK-3β Complexed with a Peptide, FRATtide, that Inhibits β-Catenin Phosphorylation  by Bax, Benjamin et al.
Structure, Vol. 9, 1143–1152, December, 2001, 2001 Elsevier Science Ltd. All rights reserved. PII S0969-2126(01)00679-7
The Structure of Phosphorylated GSK-3
Complexed with a Peptide, FRATtide,
that Inhibits -Catenin Phosphorylation
Introduction
Glycogen synthase kinase-3 (GSK-3) is a ubiquitously
expressed serine/threonine kinase that was originally
discovered and named as a kinase that phosphorylates
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In resting cells, GSK-3 is highly active, but its activity
can be inhibited physiologically in response to insulin
and/or growth factor stimulation of a relatively well-char-Summary
acterized PI3 kinase-dependent signal transduction
pathway [3]. Protein kinase B (PKB) lies on this pathwayBackground: Glycogen synthase kinase-3 (GSK-3) se-
quentially phosphorylates four serine residues on glyco- and is responsible for the direct phosphorylation of
GSK-3 on an N-terminal serine residue (residue 9 ingen synthase (GS), in the sequence SxxxSxxxSxxx-
SxxxS(p), by recognizing and phosphorylating the first GSK-3 and serine 21 in GSK-3), leading to inhibition of
GSK-3 toward its substrates, such as GS. Consequently,serine in the sequence motif SxxxS(P) (where S(p) repre-
sents a phosphoserine). FRATtide (a peptide derived from the phosphorylation and inactivation of GS is prevented,
contributing to a stimulation of glycogen synthesis [3–5].a GSK-3 binding protein) binds to GSK-3 and blocks
GSK-3 from interacting with Axin. This inhibits the Axin- Substrates of GSK-3, such as GS, that contain a “prim-
ing” phosphate located at n  4 (where n is the site ofdependent phosphorylation of -catenin by GSK-3.
phosphorylation) are phosphorylated more readily than
substrates that lack a priming site. When phosphory-
lated on serine 9, the N-terminal residues of GSK-3Results: Structures of uncomplexed Tyr216 phosphor-
ylated GSK-3 and of its complex with a peptide and a inhibit the enzyme by binding in the active site as a
pseudo-substrate [6], with residue proline 5 presumablysulfate ion both show the activation loop adopting a
conformation similar to that in the phosphorylated and blocking the active site. Interestingly, a phosphopeptide
(TTSpFAESC) corresponding to residues 7–14 of GSK-3active forms of the related kinases CDK2 and ERK2. The
sulfate ion, adjacent to Val214 on the activation loop, inhibits GSK-3 activity against primed, but not against
nonprimed, substrates [6].represents the binding site for the phosphoserine resi-
due on ‘primed’ substrates. The peptide FRATtide forms GSK-3 activity can also be inhibited in response to Wnt
growth factor signaling. Wnt molecules control numerousa helix-turn-helix motif in binding to the C-terminal lobe
of the kinase domain; the FRATtide binding site is close developmental processes by altering specific gene ex-
pression patterns [7], and deregulation of Wnt signalingto, but does not obstruct, the substrate binding channel
of GSK-3. FRATtide (and FRAT1) does not inhibit the can lead to cancer [8, 9]. Cytoplasmic -catenin is central
to the transmission of Wnt signals to the nucleus; in theactivity of GSK-3 toward GS.
absence of Wnt signaling, -catenin is phosphorylated
by GSK-3, which targets -catenin for degradation via
ubiquitin-dependent proteolysis. In response to Wnt sig-Conclusions: The Axin binding site on GSK-3 presum-
ably overlaps with that for FRATtide; its proximity to the nals, however, GSK-3 activity toward -catenin is inhib-
ited, resulting in the stabilization and accumulation ofactive site explains how Axin may act as a scaffold
protein promoting -catenin phosphorylation. Tyrosine -catenin and the activation of TCF/LEF-1 transcription
factors. The exact mechanisms by which Wnt signals216 phosphorylation can induce an active conformation
in the activation loop. Pre-phosphorylated substrate inhibit GSK-3 activity toward -catenin are unclear, but
they involve the regulation of a signaling complex thatpeptides can be modeled into the active site of the
enzyme, with the P1 residue occupying a pocket partially consists of, among other proteins, GSK-3, Dvl, Axin, APC,
and -catenin. Genetic studies have shown that Dvl, aformed by phosphotyrosine 216 and the P4 phosphoser-
ine occupying the ‘primed’ binding site. cytoplasmic protein downstream of Wnt receptors, is
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Figure 1. Structure of GSK-3
(a) Structure of crystal form A of GSK-3. Phosphotyrosine 216 (red atoms) is labeled. The activation loop is in yellow, and the side chains
of Arg 96, Arg 180, and Lys 205 are shown (yellow atoms).
(b) Structure of crystal form FS of GSK-3. The FRATtide peptide is in blue, and the sulfate ion is in red ([a] and [b] were drawn with Bobscript [46]).
(c) Final 2Fo  Fc density (1.5 ) of the FS crystal form showing the activation loop in the region of phosphotyrosine 216 and Val 214 and the
sulfate ion adjacent to Val 214.
(d) Sequence alignment of GSK-3 with CDK2 and ERK2 (and FRATtide with the Axin-derived peptide GID underneath). GSK-3 (and FRATtide)
residues in lowercase are not observed in the crystal structures reported in this paper. Secondary-structural elements in GSK-3 are indicated
above the alignment. Residues highlighted in red are phosphorylation sites in the activation loop (and serine 9 at the N terminus of GSK-3).
The conserved basic residues highlighted in yellow contact the phosphothreonine residue in CDK2 and ERK2 but contact a sulfate ion in our
crystal structure of GSK-3. Residues on GSK-3 that contact FRATtide (within 3.8 A˚) are highlighted in blue, whereas residues on the FRATtide
peptide that contact GSK-3 are highlighted in green.
essential for transmitting Wnt signals to GSK-3. Axin -catenin complex involves the mammalian protein
FRAT1 [14]. FRAT1 is homologous to GSK-3 bindinginteracts with Dvl and, in addition, binds both GSK-3
and -catenin. Axin facilitates GSK-3-mediated phos- protein (GBP), a protein identified in Xenopus embryos
that acts as a positive regulator of Wnt signaling byphorylation of -catenin by bringing GSK-3 and
-catenin into close proximity [10–13]. Consequently, stabilizing -catenin [15]. In Wnt signaling, Dvl may re-
cruit FRAT1 to the GSK-3/Axin/-catenin complex anddissociation of the GSK-3/Axin/-catenin complex pre-
vents GSK-3-mediated phosphorylation of -catenin, cause a FRAT1-mediated dissociation of GSK-3 from
Axin [16]. Since Axin is a substrate of GSK-3, dissocia-resulting in its stabilization. One proposed mechanism
for Wnt-induced dissociation of the GSK-3/Axin/ tion of Axin from GSK-3 would tend to result in the
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dephosphorylation of Axin [17]. The Wnt-induced de- ERK2 are the most closely related Ser/Thr kinases
whose structures have been determined. GSK-3phosphorylation of Axin decreases the affinity of Axin
for -catenin and allows -catenin to be released from shares some 33% amino acid sequence identity with
both CDK2 and the MAP kinase ERK2 over the corethe GSK-3/Axin/-catenin complex [18].
In vitro studies of a 39 residue peptide from the kinase domain (residues 55–345 of GSK-3, as in Figure
1d), although phylogenetic analysis suggests GSK-3 isC terminus of FRAT1, termed FRATtide, have shown that
this peptide binds GSK-3 and is sufficient for preventing more closely related to the MAP kinase ERK2 than to
CDK2 [26]. The core of the kinase domain is elaboratedAxin binding [19]. Consequently, FRATtide inhibited the
phosphorylation of Axin and -catenin, but it did not in GSK-3 by unique structural elements at the N and
C termini. At the N terminus a unique  strand, LO,inhibit GSK-3 activity toward peptides derived from
eIF2B or GS [19]. A 25 amino acid sequence in Axin, (residues Thr 38–Thr 43) forms a  hairpin with an ex-
tended 1  strand (residues 38–42 hydrogen bond toidentified as a GSK-3-interacting domain (GID), inhibits
GSK-3 and activates Wnt signaling [20]. This Axin- residues 52–56) while Thr 43 (from L0) forms two main-
chain hydrogen bonds with Phe 115 (on 4). (Note thatderived GID peptide did not inhibit activity, in vitro, to-
ward a GS-derived peptide [20]. Although the GID and secondary-structural elements are named as in cAMP
kinase, with additional elements named after the loopFRATtide peptides have a similar functionality, the
GSK-3 binding domains in FRAT and Axin do not appear in which they are found). In one molecule of GSK-3,
the N-terminal residue is Ser 29, but in the other threeto have homologous amino acid sequences.
This paper describes the crystal structures of isolated molecules the first residue for which clear density is
observed is Val 37 (in each crystal form there are twotyrosine 216-phosphorylated GSK-3 and of a complex
of GSK-3 with FRATtide and a sulfate ion. The sulfate molecules in the asymmetric unit—our construct starts
at residue 27—prior to which is a deca-His tag for whichion binds at what is the binding site for the priming
phosphorylation in substrate peptides, and in recent crys- density is not observed). The C terminus of GSK-3 has
a unique conformation from residue 343 onward; thistal structures of unphosphorylated GSK-3, a phosphate
[21] or a sulphonate [22] has been observed at this site. starts with a somewhat irregular 310 helix (338–344), in-
cludes a  turn (350–353), a short  helix (363–368), andPhosphorylation of the activation loop is a common reg-
ulatory feature of protein kinases [23], and the phospho- another  helix (373–378) capped at the N terminus by
a turn of 310 helix (370–373). The last residue for whichtyrosine 216 form of the enzyme shows the active con-
formation of the enzyme, allowing a substrate peptide interpretable density is observed is Ile 384 (our construct
terminates at asparagine 393).to be modeled into the active site. The structure with
FRATtide identifies a novel binding site, on the kinase A comparison of the two crystal forms shows that the
phosphorylated GSK-3 has a very similar conformationdomain’s C-terminal lobe, at which FRAT and Axin com-
pete for binding to GSK-3. This provides a structural in both crystal forms. However, major differences are
seen in the loop between residues 285 and 310, withexplanation as to why FRATtide inhibits the phosphory-
lation of Axin and -catenin, but not primed substrates which the FRATtide peptide makes a number of interac-
tions (see below for details). The small differences in the[19]. Small-molecule ATP-competitive inhibitors of
GSK-3 have potential therapeutic use in disease states relative orientations of the N- and C-terminal domains of
GSK-3 (rotations of less than 5 about the inter-domainassociated with elevated GSK-3 activity; such disease
states include non-insulin-dependent diabetes mellitus connecting peptide) do not effect inter-domain contacts
(the differences in domain orientation are of the sameand neurodegenerative diseases [24, 25]. Such inhibi-
tors are likely to inhibit GSK-3 activity toward all cellular order between molecules in the two different crystal
forms as they are between the two molecules in thesubstrates. Protein inhibitors such as FRAT, which ap-
pear to regulate kinase activity by modulating protein same asymmetric unit of each crystal form). Some of
the loops between secondary-structural elements in theinteractions within signaling complexes, may well inhibit
activity toward a selected subset of substrates and may N-terminal domain have high temperature factors and
appear quite flexible. The conformation of the activationbe the target for structure-based ligand design.
loop (200–226) is very similar in both crystal forms of
GSK-3; this includes the primed phosphate’s binding
Results pocket, which contains a sulfate ion in crystal form FS
(grown from ammonium sulfate), but only a water (or
The Overall Structure of Tyrosine hydroxide ion?) in crystal form A (grown from PEG at
216-Phosphorylated GSK-3 pH 8.2; see Experimental Procedures).
The crystal structures of apo GSK-3 (crystal form A)
and of GSK-3 complexed with the 39mer peptide
FRATtide and a sulphate ion (crystal form FS) were de- Conformation of the Activation Loop:
Implications for Substrate Bindingtermined and refined to 2.9 A˚ and 2.6 A˚, respectively (see
Experimental Procedures for details). The crystallized In both crystal forms, the activation loop of GSK-3 has
a conformation similar to that observed in active formsprotein was expressed in baculovirus from an N-termi-
nally deca-His-tagged construct corresponding to resi- of ERK2 [27] and CDK2 [28]. The phosphate moiety of
phosphotyrosine 216 of GSK-3 makes interactions withdues 27–393 of human GSK-3 and was phosphorylated
on tyrosine 216 in the activation loop. arginines 220 and 223. TyrP 216 in GSK-3 occupies a
similar position to phosphotyrosine 185 in the MAP ki-The overall structure of GSK-3 (shown in Figure 1)
is similar to that of other protein kinases. CDK2 and nase ERK2, but in GSK-3 it is some 1.5 A˚ farther away
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from the substrate binding groove than TyrP 185 in ERK2
(Figure 2). This fact partially accounts for the wider sub-
strate specificity of GSK-3 at the P1 position (tyrosine
216 in GSK-3 forms part of the binding pocket for the
P1 residue of the substrate - see below). The phosphory-
lation of tyrosine 216 in GSK-3 is important for activity
[29, 30] and presumably helps stabilize the activation
loop in an active conformation.
In the FS crystal form (crystallized from 1.6 M ammo-
nium sulfate), we see a sulfate ion adjacent to Val 214
(Figure 1c). This sulfate ion makes hydrogen bonds to
three basic residues, arginines 96 and 180 and lysine
205. These three residues are conserved as basic resi-
dues in CDK2 and ERK2 where, in crystal structures
of active forms of these proteins, they interact with a
phosphothreonine residue on the activation loop. This
residue is Thr 160 in CDK2 [28] and Thr 183 in ERK2
[27] (see Figure 2). Many GSK-3 substrates require
a priming phosphorylation on a serine residue four
residues C-terminal to the phosphorylatable serine or
threonine residue. The binding site for this preexisting
phosphate moiety on primed substrates is probably rep-
resented by the sulfate ion. Frame et al., 2001 [6] have
shown that an Arg96Ala mutant of GSK-3 has a se-
verely impaired ability to phosphorylate primed sub-
strates and that this mutant is resistant to inhibition by
phosphorylation on Ser 9.
A primed substrate peptide from GS (sequence
RHSSPHQSp, where Sp represents a phosphoserine
and S is the phosphorylatable residue) was modeled
into the active site of GSK-3 (Figure 2; see Experimental
Procedures for details). The terminal phosphoserine res-
idue of this substrate peptide was positioned so that its
phosphate moiety occupied the same position as the
sulfate ion in the FS crystal form and was thus coordi-
nated by arginines 96 and 180 and lysine 205. The proline
residue at the P1 position of the substrate peptide occu-
pied a depression partially formed by the aromatic ring
of phosphotyrosine 216, but this P1 pocket is more open
in GSK-3 than in the MAP kinase ERK2 because the
phosphotyrosine 216 has moved down and away from
the substrate (compared to phosphotyrosine 185 in
ERK2). ERK2 has a strong preference for proline resi-
dues at the P1 position, whereas GSK-3 substrates have
a wider range of P1 residues. The modeled substrate
peptide made few other specific contacts (apart from
the contacts of the phosphorylatable serine to Asp 181
and Lys 183).
The substrate binding groove, between the two lobes
Figure 2. The Activation Loop and Substrate Binding of the kinase domain, is above (in Figure 3a) the FRAT-
(a) The structure of CDK2 (red) with a substrate peptide (purple) and tide binding site, so that there is no steric clash between
a nonhydrolizable analog of ATP (labeled ATP; only the terminal a modeled substrate and the FRATtide.
phosphate group is visible; PDB code 1QMZ; [28]). Ser 5 is the
phosphorylatable serine in the substrate. Lysine 8 from the substrate
peptide interacts with phosphothreonine 160.
The FRATtide Binding Site(b) Superposed structures of CDK2 (red), ERK2 (yellow; PDB code
Is on the C-Terminal Lobe2ERK; [27]) and GSK-3 (green; FS crystal form). The sulfate in GSK-3
is labeled and superposes on phosphothreonine residues in CDK2 In the crystal structure of the GSK-3 with FRATtide (a
and ERK2. peptide that corresponds to residues 188–226 of the
(c) Coordinates of GSK-3 (green) are shown with a substrate peptide GSK-3 binding protein FRAT1), electron density is ob-
(blue) modeled in the active site. The peptide has been modeled on
served for residues 198–222 of the peptide (other FRAT-the peptide in the CDK2 crystal structure (a) with the phosphothreonine
tide residues are disordered). The FRATtide comprisesresidue at position 9 modeled with its phosphate group occupying the
two  helices (1 and 2), which form a helix-turn-helixposition occupied by the sulfate in the crystal structure of the FS
crystal form of GSK-3. The figure was drawn with GRASP [47]. motif that packs against the C-terminal lobe of GSK-3
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(Figures 1 and 3). The binding of FRATtide causes a
change in the position of residues 286–296 of GSK-3.
In crystal form A (without FRATtide), residues 286–296
pack close to and partially cover phenylalanine 229 and
the hydrophobic surface of helix G (the 286–296 loop
has high temperature factors in crystal form A, sug-
gesting that the packing of Phe 291, Phe 293, and other
residues against helix G is not optimal). Upon binding,
FRATtide residues 288–294 of GSK-3 move approxi-
mately 6 A˚ away from helix G and open up a hydrophobic
groove, between helix G and the 288–294 loop. The
second, amphipathic, 2 helix of FRATtide slots neatly
into this groove (FRATtide residues that interact with
GSK-3 are highlighted in green on the sequence align-
ment in Figure 1d, whereas GSK-3 residues that interact
with FRATtide are highlighted in blue; note that Lys 271
of GSK-3 makes van der Waals interactions with FRAT-
tide via hydrophobic parts of its side chain). The first
helix of FRATtide, 1, is also amphipathic but is less
buried in packing against a flatter part of the surface of
GSK-3. The N-terminal end of this 1 helix has higher
temperature factors than the rest of FRATtide and, at
His 200, comes quite close (approximately 4.3 A˚) to the
side chain of phosphotyrosine 216 in the activation loop
of GSK-3.
Although much of the interaction of FRATtide with
GSK-3 is mediated by hydrophobic interactions, an ex-
quisite network of hydrogen bonds is formed to the
N-terminal residues of the 2 helix of FRATtide (Figure
3). The side-chain functions of Tyr 288 and Glu 290
from GSK-3 make hydrogen bonds with the main-chain
amides of Leu 212, Ile 213, and Lys 214 from FRATtide
at the N terminus of 2. The side-chain nitrogen function
of Lys 214 from FRATtide also interacts with Glu 290
from GSK-3 and, via a water molecule, with the main
chain. The N-terminal leucine and isoleucine from the
2 helix of FRATtide are deeply buried in GSK-3 and,
with the neighboring Lys and Glu in the sequence LIKE,
appear to be a major determinant of FRAT binding to
GSK-3 ([15]; see discussion below).
The Axin-derived GSK-3 binding peptide GID [20] also
possesses a Leu-Ile sequence and is aligned with FRAT-
tide on this basis in Figure 1d. Smalley et al., 1999 [12]
found that mutation of this leucine residue in mouse
Axin abolished binding to GSK-3.
An Axin-Derived Peptide Competes for the
FRATtide Binding Site on GSK-3
The Axin-derived peptide called GID can compete with
FRATtide for binding to GSK-3—although it binds with
lower affinity (Kd  3.2  1.1 	M, cf FRATtide Kd  39 
7 nM; Culbert et al., 2001 [31]). Presumably, GID binds
(b) The FRATtide peptide is shown with its backbone represented
as a blue worm and hydrophobic side-chains contacting GSK-3 in
green. The amino terminus of the FRATtide peptide (Asp 198) is
toward the top of the figure. GSK-3 is represented as a solid surface,
with negative electrostatic potential (red) due to Glu 288 from GSK-3
Figure 3. The GSK-3/FRATtide Interaction adjacent to the N terminus of the second helix of FRATtide.
(a) Surface representation of the structure of GSK-3 (green), FRAT- (c) Hydrogen bonds (dotted lines) between Tyr 288 and Glu 300 from
tide (blue), and the sulfate ion (red). The N terminus of the FRATtide GSK-3 (green) and the residues Leu 212, Ile 213, and Lys 214 from
approaches the sulfate ion (and the substrate binding groove). The FRATtide (blue). Hydrogen bonds from Lys 214 of FRATtide to a
C terminus of FRATtide is toward the bottom of the picture. water and thence to the backbone of GSK-3 are also shown.
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[22] at the primed binding site and have thus suggestedTable 1. TAMRA-FRATtide Ligand Displacement Assay
that the binding of phosphorylated substrates to GSK-3
GID Kd (	M) may help to induce an active conformation in the activa-WT 3.2  1.1
tion loop. The conformation of the activation loop weL396M 12  4
observe in the absence of a sulfate ion at the primedL392P 

100
L392M 33  8 site (crystal form A) is almost identical to that observed
in the presence of a sulfate ion, suggesting that phos-
phorylation of tyrosine 216 is sufficient to induce the
correct conformation in the activation loop (residuesto the same site on GSK-3 as FRATtide. Although the
220–226 in GSK-3). The crystal structure of the phos-sequence of GID has little sequence identity to FRAT-
phorylated form of GSK-3 therefore suggests that tyro-tide, it does possess a Leu-Ile sequence (residues 392
sine 216 phosphorylation may be critical for regulatingand 393; see Figure 1d) in a potential helix-forming re-
activity against non-primed substrates.gion (LIHRLEAVQR, where the underlined residues are
Studies of the activity of a Y216F mutation of GSK-3predicted to interact with GSK-3 based on the alignment
have suggested that the substitution of phenylanine forin Figure 1d). Smalley et al., 1999 [12] found that a muta-
tyrosine 216 lowers activity some 5- to 10-fold [29, 30].tion (L521P) equivalent to L392P in mouse Axin abol-
However, these studies did not distinguish betweenished binding to GSK-3, and Webster et al., 2000 [32]
primed and non-primed substrates, and the Tyr 216 formidentified a L396M mutation in three human cancer-
of the enzyme was not necessarily fully phosphorylated.derived cell lines that interfered with Axin’s ability to
Although in Dictyostelium the tyrosine kinase ZAK1 acti-bind GSK-3. The effect of mutating these residues on
vates GSK-3 to direct cell fate specification [33], thethe binding of GID to GSK-3 is shown in Table 1. The
regulatory role of Tyr 216 phosphorylation in signalingmutation of Leu 392 or Leu 396 to Met lowered, but did
in mammalian cells is less clear. The main method bynot abolish, the binding of GID to GSK-3, consistent
which insulin inhibits GSK-3 activity is by the phosphory-with these residues being on the hydrophobic face of a
lation of serine 9 by PKB [4, 34], but tyrosine dephos-helix interacting with GSK-3. The mutation of Leu 392
phorylation of GSK-3 may also play a role in responseto proline abolished the binding of GID to GSK-3, consis-
to extracellular signals [35]. Nerve growth factor (NGF)tent with the side-chain hydroxyl of Tyr 288 from GSK-3
withdrawal from PC12 cells led to increased phosphory-forming a hydrogen bond to the main-chain amide of
lation at Tyr 216, GSK-3 activity, and cell death [36].Leu 392 (as observed in the GSK-3-FRATtide complex
This increased cell death may have been at least partiallybetween Tyr 288 and Leu 212; see Figure 3). To con-
due to enhanced phosphorylation and degradation ofclude, the data are consistent with residues 393–401 of
-catenin by GSK-3. Crowder and Freeman [37] haveAxin forming an ampipathic  helix that binds to GSK-3
shown that expression of FRAT1 rescues neurons fromin manner similar, but not identical, to that of the 2
cell death induced by the inhibition of PI-3 kinase orhelix on FRATtide. The sequence alignment in Figure 1d
PKB, but not from cell death caused by NGF withdrawal.suggests that GID would not possess an 1 helix similar
Culbert et al. [31] have recently shown that FRAT1 over-to that on FRATtide. While the footprint of Axin on GSK-3
expression in PC12 cells is neuroprotective and inhibitsoverlaps with that of FRATtide, it is unlikely to be identi-
phosphorylation of tau and -catenin but that FRAT1cal. Yuan et al., 1999 [30] have shown that a Y216F
overexpression is a less-potent method of neuroprotec-mutant of GSK-3 still binds FRAT but has a reduced
tion than ATP-competitive inhibitors of GSK-3. Overex-affinity for Axin, suggesting that Axin may interact di-
pression of FRAT1 did not inhibit activity toward GS [31].rectly with TyrP 216.
The FRATtide peptide adopts a helix-turn-helix con-
formation and, in packing against the C-terminal lobe
Discussion of GSK-3, induces a change in conformation of a loop
in the region between helices G and H. Members of the
Phosphorylation of residues within the activation loop CDK2, Erk (MAP), Clk, and GSK-3 kinase families all
is a common mechanism for regulating the activity of have a large insertion (compared to those of other ki-
kinases [23]. In the MAP kinase ERK2, two sites on nases [26]) in their amino acid sequences in this region,
the activation loop, Thr 183 and Tyr 185, need to be and here we show this region to be functionally signifi-
phosphorylated for maximum activity [27]. In GSK-3, the cant in GSK-3. In particular the side-chain functions of
binding sites for both phosphate groups are conserved, Tyr 288 and Glu 290 from GSK-3 recognize the largely
and phosphotyrosine 216 in GSK-3 is structurally equiv- buried N-terminal end of the second  helix (sequence
alent to phosphotyrosine 185 in ERK2. However, the LIKE) of FRATtide. Mutation of the KE sequence to AQ
residue equivalent to Thr 183 (in ERK2) is Val 214, and in the Xenopus FRAT homolog, GBP, greatly reduced
the phosphate binding site adjacent to this residue is binding to Xenopus GSK-3 [15], although binding of this
used in GSK-3 for recognizing the priming phosphoryla- mutant to GSK-3 could be detected in the presence of
tion on the substrate or the PKB inhibitory phosphoryla- Xenopus Dsh [16]. While Lys 214 from the LIKE se-
tion site at the amino terminus of GSK-3 [6, 21, 22]. The quence makes a direct interaction with GSK-3 (Figure
substitution of a valine for the phosphothreonine seems 3c), the side chain of Glu 215 does not interact directly
to have slightly lowered the bottom lip of the substrate with GSK-3 but stabilizes the helical conformation of
binding groove in GSK-3 (compared to ERK2; see Figure FRATtide by interacting with Arg 218 and Arg 219 one
2). Recently published structures of unphosphorylated turn down the 2 helix. One model for the function of
FRAT in Wnt signaling is that it displaces the scaffoldGSK-3 have a phosphate ion [21] or sulphonate moiety
Structure of GSK-3-FRATtide Complex
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Figure 4. Source 15S Elution Profile
Source 15S elution profile showing separa-
tion of the phosphorylated and nonphosphor-
ylated forms of GSK-3 (see Experimental
Procedures for details).
protein Axin from GSK-3 and thus inhibits GSK-3 from Small-molecule inhibitors that occupied the sulfate
binding site would have the potential to inhibit GSK-3phosphorylating -catenin. Consistent with this model
is the observation that the Axin-derived peptide GID activity against primed substrates such as glycogen
synthase, and small-molecule mimetics of FRATtidecompetes with FRATtide for binding to GSK-3 [31]. Mu-
tations in GID (Table 1) that lower its affinity for GSK-3 may be neuroprotective. At least three regulatory genes
in the Wnt signaling pathway are mutated in primaryare consistent with the hypothesis that the sequence
392-LIHRLEAVQR-401 forms an amphipathic helix that human cancers [39]. Molecules that bound to FRAT and
prevented FRAT from displacing Axin on GSK-3 wouldbinds to GSK-3 at a site similar to that in FRATtide.
The L392P mutation abolishes binding of GID to GSK-3 inhibit Wnt pathways that signal via FRAT-mediated dis-
placement of Axin and could potentially be useful in(Table 1), and this mutation in mouse Axin (L521P) inhib-
its GSK-3 binding in cellular assays [12]. some human cancers.
Potent and selective ATP-competitive inhibitors of
GSK-3 [38] stimulate glycogen synthesis in human liver Biological Implications
cells and induce the expression of a -catenin-LEF/
TCF-regulated reporter gene in HEK293 cells [24]. These Glycogen synthase kinase-3 is inhibited in response
to insulin signaling when it is phosphorylated by PKBsmall-molecule inhibitors protect primary neurones from
cell death induced by reduced PI-3 kinase pathway ac- on serine 9. The exact mechanism(s) by which GSK-3
activity toward -catenin is inhibited in Wnt signalingtivity [25]. The elucidation of the crystal structure of
tyrosine 216-phosphorylated GSK-3 bound to FRATtide pathways is less clear, but it may involve the GSK-3
binding protein FRAT1.and a sulfate ion allows us to structurally dissect differ-
ent ways in which GSK-3 function can be regulated. The crystal structures of uncomplexed Tyr 216-phos-
Table 2. Crystallographic Data and Refinement Statistics
Crystal Form A, Native phospho-GSK-3 FS, FRATtide phospho-GSK-3
Data Collection
Space group P21 R32
Cell a, b, c (A˚) 67.6, 115.4, 67.7 (  101.98) 153.1, 153.1, 213.4
Maximal resolution 2.89 A˚ 2.60 A˚
Total/unique reflections 32,874/17,737 333,047/29,716
Completeness 78% 99.9%
Rsyma (%) 6.7% (20.1%) 6.6% (44.8%)
Refinement
Protein atoms 5,550 6,059
Residues 696 755
Other atoms 21 (5 H2O) 168 (140 H2O, 3 SO42, 1 Tris)
Rcryst/Rfree2 (%) 21.9%/29.1% 19.6%/26.2%
rmsd bond lengths (A˚) 0.013 0.007
rmsd bond angles (degrees) 2.1 1.3
a Rsym  |Ii  I
|/Ii, where Ii is the intensity of the ith observation of a reflection and I
 is the mean intensity of the reflection.
2 Rcryst  ||Fobs  |Fcal||/|Fobs|, where |Fobs| and |Fcal| are the observed and calculated structure factor amplitudes for a reflection. Rfree was
calculated from a disjoint set of reflections (8% of total form A, 5% form FS) selected in thin resolution shells (to avoid possible bias due to
NCS in each crystal form).
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of two peaks from the cation exchange column by electrosprayphorylated GSK-3 and its complex with a peptide and
Liquid Chromatography-Mass Spectroscopy (Water 2690 HPLC;a sulfate ion provide a structural explanation for three
Polymer Labs PLRP-S, 300A, 5	m, 150 2.1 mm, H2O:ACN gradientways in which GSK-3 activity can be regulated. Phos-
15%–75% over 24 min with 0.05% TFA; Micromass LC-T) revealed
phorylation of tyrosine 216 causes the activation loop a mass difference of 80 Da, corresponding to a phosphate ion.
of GSK-3 to adopt an active conformation and defines
the P1 specificty pocket for substrates. The binding of
Crystallization of the Phosphorylated FormGSK-3 substrates containing a primed phosphoserine
without and with FRATtideresidue also seems to promote an active conformation
Initial crystallization experiments gave crystals with the phosphory-of the activation loop and may help to promote the
lated, but not with the unphosphorylated, GSK-3- protein. The
correct orientation of the N- and C-terminal lobes of the purified protein (concentration up to 4 mg/ml) was crystallized by
kinase domain for catalysis. Upon phosphorylation by the hanging-drop vapor diffusion method against wells containing
100 mM Tris Acetate (pH 8.2), 125 mM NaCl, and 6%–14% PEGPKB, serine 9 at the N terminus of GSK-3 will occupy the
8000 (temperature, 277 K). This gave crystal form A (Table 2), whichprimed binding site, with the N-terminal residues of GSK-3
yielded a 2.9 A˚ data set at EH2 on beamline ID14 at the ESRFthen blocking its own active site as a pseudosubstrate.
(European Synchrotron Radiation Facility, Grenoble); crystals wereThe FRATtide peptide forms two  helices, which bind
frozen by serial transfer to 20% glycerol.
to the C-terminal lobe of the kinase domain adjacent Incubation of 39mer peptide FRATtide (0.2–2 mg/ml; purchased
to, but not obstructing, the substrate access channel. from California Peptide Research) with phosphorylated GSK-3 (1–4
mg/ml) improved the solubility of the protein and gave crystals inFRATtide competes with Axin for binding to GSK-3, and
space group R32 (Table 2; crystal form FS, crystallized from 1.4–2.2the footprint of Axin on GSK-3 is expected to be similar
M ammonium sulfate [pH 7–8] with 100 mM Tris or Hepes buffer atto that of FRATtide. A predicted amphipathic helix in
room temperature). These crystals were frozen by serial transfer toAxin may bind to GSK-3 in a similar manner to the sec-
25% ethylene glycol ( crystallization buffer).
ond helix of FRATtide. The structure of the GSK-3/FRAT-
tide complex helps to explain how Axin can function as
a scaffolding protein that brings GSK-3 and -catenin Structure Solution and Refinement
X-ray data were collected at EH2 of ID14 at the ESRF, Grenoble.together. The GSK-3/FRATtide structure provides an ex-
Data from crystal form A (space group P21) were somewhat aniso-planation as to why FRATtide does not inhibit GSK-3
tropic, and each image was processed with MOSFLM [41] to afrom phosphorylating glycogen synthase but does in-
resolution at which I/sigmaI 
 2.5. This gave a data set that was
hibit GSK-3 from binding Axin (and phosphorylating more than 90% complete in most resolution shells but less complete
-catenin). The structure can be used as a template in at high resolution. Diffraction data from crystal form FS (FRATtide
crystal form, space group R32) were not noticeably anisotropic; thestructure-based drug design for designing inhibitors
high Rsym in the high-resolution shell for this data set (44.8%; Tablethat inhibit or activate GSK-3 toward specific classes
2) is probably due to the high redundancy (11.2), and these dataof substrates, which may be associated with disease
were useful in refinement (Rcryst/Rfree  29.1%/32.2% for the high-states such as diabetes, neurodegenerative disease, or
resolution shell data at end of refinement). Diffraction data (purified
cancers. from Sf9 cells) that were collected from SeMet-labeled GSK-3 and
cocrystallized with FRATtide were disappointing (3.3 A˚) and were
not used in the structure determination.Experimental Procedures
The positions of the two molecules in the asymmetric unit of
crystal form A (space group P21) were located by molecular replace-Expression and Purification
ment; coordinates of doubly phosphorylated ERK2 were used as aA construct corresponding to residues 27–393 of GSK-3 was de-
search model (PDB code 2ERK [27]). The rotation function, calcu-signed based on sequence conservation and expressed with an
lated with Amore [42], gave clear solutions to the rotation functionN-terminal deca-His in Sf9 cells (cells were grown and infected with
and translation function peaks above noise. The molecular replace-recombinant baculovirus as described previously [40]). Frozen cells
ment solution was consistent with the noncrystallographic 2-foldwere defrosted in buffer A (10 mM MOPS [pH 7.0], 300 mM NaCl,
axis, perpendicular to the crystallographic 21, which was clearly10% glycerol, 10 mM -mercaptoethanol, 50 mM NaF, 1 mM Na
evident in the self-rotation function (and in the diffraction pattern).orthovanadate, 1 mM benzamidine, 1 mM PMSF, 1 	g/ml bestatin,
After three rounds of refinement with CNX [43] in crystal form A, the1 	g/ml lepeptin, 1 	g/ml aprotinin) and disrupted by dounce ho-
R factor (Rfree) had decreased to 35.5% (42.4%) on data to 2.9 A˚mogenization, on ice. Cell debris was removed by centrifugation
(maps were averaged around the noncrystallographic 2-fold axis(48,000 g for 60 min at 4C), and the supernatent was contacted
with the RAVE suite [44]).with 10 ml of NiNTA Supreflow (QIAGEN) for 4 hr at 4C. NiNTA
Crystal form FS (with FRATtide, space group R32) was solved bybeads were recovered by centrifugation (2000 g for 10 min at 4C),
molecular replacement with coordinates from crystal form A (afterpacked into an XK16 column (Amersham Pharmacia), and washed
three rounds of refinement), which gave a clear solution (note thatwith 10 Bv (Bed volumes) buffer A, 10 Bv buffer A  1 M NaCl, and
the two molecules in R32 gave rise to a single peak in the rotation20 Bv buffer A  100 mM imidazole before they were eluted with 20
function). The R32 solution had an initial R factor (Rfree) of 41.7%Bv buffer A 500 mM imidazole on an AKTA Purifier 100 (Amersham
(46.7%) on data to 2.8 A˚ after rigid-body refinement in CNX. SevenPharmacia). Fractions were analyzed with the Bradford assay
rounds of refinement in the R32 crystal form (interspersed with re-(Pierce) and reducing SDS PAGE (Novex).
builds on the graphics with XTALVIEW [45]) reduced the R factorCation exchange was performed with Source 15S (Amersham
(Rfree) to 24.8% (28.8%) on data to 2.6 A˚. These refined coordinatesPharmacia). Fractions from the immobilized metal ion affinity chro-
for GSK-3 were transformed back to crystal form A, for whichmatography were pooled, and the buffer was exchanged for buffer
initial rigid-body refinement gave an R factor (Rfree) of 27.4% (31.6%).B (20 mM MOPS [pH 7.0], 50 mM NaCl, 1 mM DTT, 10% glycerol,
Further refinement gave statistics as shown in Table 2. The final1 mM Na orthovanadate, 1 mM benzamidine, 0.2 mM PMSF) by the
structure for crystal form FS shows only two residues from theuse of G25M (Amersham Pharmacia). The fractions were then loaded
Ramachandran plot in disallowed regions; these are both cysteineonto an 8 ml Source 15S column, HR10 (Amersham Pharmacia).
218 (from molecules A and B). In ERK2 the residue that is equivalentThis was washed with 5 Bv of buffer B before being eluted with a
to cysteine 218, Ala 187, has a left-handed conformation (φ  70,linear NaCl gradient of 0–500 mM over 50 Bv, 500–1000 mM NaCl
  158 [27]); similar conformations for this residue are observedover 5 Bv, and 1000 mM at 5 Bv. Five milliliter fractions were
collected at 150 cmh 1 with an AKTA purifier 100 (Figure 4). Analysis in active CDK2 [28] and in our GSK-3 structure.
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Model of Substrate Peptide GSK-3 Complex 12. Smalley, M.J., et al., and Dale, T.C. (1999). Interaction of Axin
and Dvl-2 proteins regulating Dvl-2 stimluated TCF-dependentThe crystal structure of the phosphorylated CDK2/cyclin A/substrate
peptide/ATP analog complex (PDB code 1QMZ [28]) was super- transcription. EMBO J. 18, 2823–2835.
13. Sakanaka, C., Weiss, J.B., and Williams, L.T. (1998). Bridgingposed on molecule A of the FS crystal form of GSK-3 (see Figure
2). The substrate peptide (sequence HHASPRK)in the CDK2 active of -catenin and glycogen synthase kinase-3 by Axin and inhi-
bition of -catenin-meditated transcription. Proc. Nat. Acad.site was then used as a template for modeling a portion of the
glycogen synthase substrate, sequence RHSSPHQSp (where Sp Sci. USA. 95, 3020–3023.
14. Jonkers, J., Korswagen, H.C., Acton, D., Breuer, M., and Berns,represents a phosphoserine) according to the following alignment:
CDK2 substrate HHASPRK A. (1997). Activation of a novel proto-oncogene, FRAT1, contrib-
utes to progression of mouse T-cell lymphomas. EMBO J. 16,GSK-3 substrate RHSSPHQSp
The terminal lysine residue in the CDK2 substrate peptide inter- 441–450.
15. Yost, C., Farr, G.H. III, Pierce, S.B., Ferkey, D.M., Chen, M.M.,acts with the phosphate of phosphothreonine 160 in CDK2; the
terminal phosphate of the phosphoserine residue in the GSK-3 sub- and Kimelman, D. (1998). GBP, an inhibitor of GSK-3, is impli-
cated in Xenopus development and oncogensis. Cell 93, 1031–strate was positioned to superpose on the sulfate ion in the GSK-3
crystal structure and thus occupied a similar position to the phos- 1041.
16. Li, L., et al., and Wu, D. (1999). Axin and FRAT1 interact withphate on phosphothreonine 160 in CDK2. The resulting model of
GSK-3 substrate peptide (minus sulfate ion) is shown in Figure 2c. Dvl and GSK, bridging Dvl to GSK in Wnt-meditated regulation
of LEF-1. EMBO J. 18, 4233–4240.
17. Hsu, W., Zeng, L., and Costantini, F. (1999). Identification ofFluorescence Binding Assay for FRATtide Antagonists
a domain of Axin that binds to the serine/threonine proteinThe affinities of GID mutants (Table 1) were assessed with a fluores-
phosphatase 2A and a self-binding domain. J. Biol. Chem. 274,cently labeled (TAMRA) FRATtide ligand displacement assay as de-
3439–3445.scribed [31].
18. Willert, K., Shibamoto, S., and Nusse, R. (1999). Wnt-induced
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Accession Numbers
Structure factors and coordinates for the GSK-3/FRATtide com-
plex have been deposited in the Protein Data Bank and assigned
the accession code 1gng.
